
Santiago Grau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6428486/publications.pdf Version: 2024-02-01



SANTIACO CRALL

#	Article	IF	CITATIONS
1	Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Review of Anti-Infective Therapy, 2022, 20, 179-197.	2.0	9
2	COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing. Vaccines, 2022, 10, 594.	2.1	4
3	Ceftaroline removal during plasmapheresis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, 40, 216-217.	0.2	0
4	Therapeutic drug monitoring of colistin in plasma and cerebrospinal fluid in meningoventriculitis caused by a carbapenem-resistant Enterobacter cloacae. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, 40, 277-278.	0.2	0
5	The costâ€effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain. Mycoses, 2021, 64, 66-77.	1.8	11
6	Antibiotic consumption trends among acute care hospitals in Catalonia (2008–2016): impact of different adjustments on the results. Expert Review of Anti-Infective Therapy, 2021, 19, 245-251.	2.0	4
7	Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics, 2021, 10, 132.	1.5	56
8	Osteoarticular Cryptococcosis Successfully Treated with High-Dose Liposomal Amphotericin B Followed by Oral Fluconazole. Infection and Drug Resistance, 2021, Volume 14, 719-722.	1.1	5
9	A Loading Micafungin Dose in Critically III Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring, 2021, 43, 747-755.	1.0	3
10	Therapeutic drug monitoring of colistin in plasma and cerebrospinal fluid in meningoventriculitis caused by a carbapenem-resistant Enterobacter cloacae. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, , .	0.3	0
11	Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by Escherichia coli or Klebsiella pneumoniae: The Role of Prior Exposure to Fluoroquinolones. Antibiotics, 2021, 10, 582.	1.5	8
12	Nebulized Micafungin Treatment for <i>Scopulariopsis</i> / <i>Microascus</i> Tracheobronchitis in Lung Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	3
13	Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically III Patients. Antibiotics, 2021, 10, 666.	1.5	1
14	Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia: A Cohort Study. Antibiotics, 2021, 10, 716.	1.5	5
15	Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement. Clinical Microbiology and Infection, 2021, 27, 1698.e1-1698.e4.	2.8	6
16	Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole. Mycoses, 2021, 64, 1213-1222.	1.8	2
17	Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics, 2021, 10, 943.	1.5	36
18	Impact of Generic Entry on Hospital Antimicrobial Use: A Retrospective Quasi-Experimental Interrupted Time Series Analysis. Antibiotics, 2021, 10, 1149.	1.5	0

SANTIAGO GRAU

#	Article	IF	CITATIONS
19	Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. Antibiotics, 2021, 10, 1296.	1.5	4
20	Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. European Journal of Gastroenterology and Hepatology, 2021, 32, 214-222.	0.8	3
21	Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Scientific Reports, 2021, 11, 22178.	1.6	6
22	Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. Frontiers in Pharmacology, 2021, 12, 752879.	1.6	1
23	lvermectin: a pathway out of the pandemic or another dead end?. Expert Review of Anti-Infective Therapy, 2021, , 1-3.	2.0	1
24	Personalized antimicrobial therapy in critical and elderly patients Farmacia Hospitalaria, 2021, 45, 64-76.	0.6	0
25	Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane. Perfusion (United Kingdom), 2020, 35, 267-270.	0.5	4
26	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Medical Economics, 2020, 23, 148-155.	1.0	1
27	Which type of bone releases the most vancomycin? Comparison of spongious bone, cortical powder and cortico-spongious bone. Cell and Tissue Banking, 2020, 21, 131-137.	0.5	1
28	Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008–18. JAC-Antimicrobial Resistance, 2020, 2, dlaa079.	0.9	2
29	Finding the Dose for Ceftolozane-Tazobactam in Critically III Children with and without Acute Kidney Injury. Antibiotics, 2020, 9, 887.	1.5	11
30	Strong opioid consumption and its correlation with pain intensity and inpatient complexity. A 6â€year analysis in a tertiary hospital. European Journal of Pain, 2020, 24, 1151-1159.	1.4	0
31	Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?. Journal of Clinical Medicine, 2020, 9, 514.	1.0	27
32	Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study. Infectious Diseases and Therapy, 2020, 9, 151-163.	1.8	3
33	Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 36-40.	0.3	10
34	Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. Journal of Infection, 2019, 79, 253-261.	1.7	28
35	Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 2019, 32, .	5.7	489
36	Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. Journal of Antimicrobial Chemotherapy, 2019, 74, 3268-3273.	1.3	12

SANTIAGO GRAU

#	Article	IF	CITATIONS
37	Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?. Molecules, 2019, 24, 530.	1.7	7
38	Successful ceftolozaneâ€tazobactam rescue therapy in a child with endocarditis caused by multidrugâ€resistant <scp><i>Pseudomonas aeruginosa</i></scp> . Journal of Paediatrics and Child Health, 2019, 55, 985-987.	0.4	14
39	Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. Therapeutic Drug Monitoring, 2019, 41, 732-739.	1.0	17
40	Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. Therapeutic Drug Monitoring, 2019, 41, 376-382.	1.0	4
41	A Before-and-After Study of the Effectiveness of an Antimicrobial Stewardship Program in Critical Care. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	37
42	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112.	0.5	7
43	Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in Therapy, 2018, 35, 1920-1934.	1.3	17
44	Extremely high levels of vancomycin can cause severe renal toxicity. Infection and Drug Resistance, 2018, Volume 11, 1027-1030.	1.1	21
45	Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 39-47.	0.7	5
46	Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. Advances in Therapy, 2017, 34, 2104-2119.	1.3	9
47	Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in critically-ill patients: systematic review. Farmacia Hospitalaria, 2017, 41, 187-203.	0.6	4
48	Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Drug Design, Development and Therapy, 2016, Volume11, 65-82.	2.0	18
49	Can we guarantee less nephrotoxicity when vancomycin is administered by continuous infusion?. International Journal of Antimicrobial Agents, 2016, 48, 116-117.	1.1	5
50	The Delphi method applied to fungal infection: There is still some way to go. Revista Iberoamericana De Micologia, 2016, 33, 185-186.	0.4	0
51	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, 2016, 71, 696-702.	1.3	37
52	Severe thrombocytopenia caused by linezolid poisoning in an underweight critically ill patient with renal impairment treated with the recommended doses. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 213-214.	0.3	4
53	Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008–2013. Expert Review of Anti-Infective Therapy, 2016, 14, 137-144.	2.0	10
54	Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 652-654.	0.3	8

SANTIAGO GRAU

#	Article	IF	CITATIONS
55	Patient risk factors for developing a drug-related problem in a cardiology ward. Therapeutics and Clinical Risk Management, 2015, 11, 9.	0.9	34
56	The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. International Journal of Infectious Diseases, 2015, 36, 31-38.	1.5	23
57	Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections. Journal of Infection, 2015, 71, 604-607.	1.7	16
58	Antifungal therapeutic drug monitoring: When, how, and why. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 295-297.	0.3	4
59	Comment on: Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 3168-3168.	1.3	2
60	Pharmacokinetics/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapy. Journal of Critical Care, 2015, 30, 1129-1130.	1.0	6
61	Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain. Journal of Antimicrobial Chemotherapy, 2014, 70, 1193-7.	1.3	11
62	Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 1624-1632.	1.3	35
63	Comment on: Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. Journal of Antimicrobial Chemotherapy, 2014, 69, 3165-3166.	1.3	3
64	How to measure and monitor antimicrobial consumption and resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 16-24.	0.3	34
65	Antibiotic consumption at 46 VINCat hospitals from 2007 to 2009, stratified by hospital size and clinical services. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2012, 30, 43-51.	0.3	10
66	Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study. European Journal of Drug Metabolism and Pharmacokinetics, 0, , .	0.6	2